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BACKGROUND: Recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) is a common cancer with
high recurrence and mortality. Current treatments have low response rates (RRs).
METHODS: Fifty-three patients with R/M SCCHN received continuous oral buparlisib. In parallel, patient-derived xenografts (PDXs)
were established in mice to evaluate resistance mechanisms and efficacy of buparlisib/cetuximab combination. Baseline and on-
treatment tumour genomes and transcriptomes were sequenced. Based on the integrated clinical and PDX data, 11 patients with
progression under buparlisib monotherapy were treated with a combination of buparlisib and cetuximab.
RESULTS: For buparlisib monotherapy, disease control rate (DCR) was 49%, RR was 3% and median progression-free survival (PFS)
and overall survival (OS) were 63 and 143 days, respectively. For combination therapy, DCR was 91%, RR was 18% and median PFS
and OS were 111 and 206 days, respectively. Four PDX models were originated from patients enrolled in the current clinical trial.
While buparlisib alone did not inhibit tumour growth, combination therapy achieved tumour inhibition in three of seven PDXs.
Genes associated with apoptosis and cell-cycle arrest were expressed at higher levels with combination treatment than with
buparlisib or cetuximab alone.
CONCLUSIONS: The buparlisib/cetuximab combination has significant promise as a treatment strategy for R/M SCCHN.
CLINICAL TRIAL REGISTRATION: NCT01527877.
British Journal of Cancer (2020) 123:1720–1729; https://doi.org/10.1038/s41416-020-01074-2
BACKGROUND
Squamous cell carcinoma of head and neck (SCCHN) is the sixth
most frequent cancer with a dismal prognosis and high mortality.1
Low survival, in combination with the significant toxicity of current
treatment strategies, emphasises the necessity for novel thera-
pies.2 In recurrent/metastatic SCCHN (R/M SCCHN), the only
approved targeted therapy is cetuximab, a monoclonal antibody
against the epidermal growth factor receptor (EGFR), with a
response rate (RR) of 10–15%.3 Anti-programmed death 1 (PD-1)
inhibitors, including pembrolizumab and nivolumab, were
recently approved for SCCHN, which is refractory to platinum-
based therapy. Although anti-PD-1 therapy showed improved
outcomes over previous standard chemotherapies (taxane,
methotrexate or cetuximab), objective responses have been
reported in only 15–20% of patients.4–6
Recent genomic studies have suggested potential therapeutic
opportunities. Genetic alterations of the phosphatidylinositol 3-
kinase (PI3K)–mTOR cell signalling pathway are common, particu-
larly gain-of-function mutations of PI3K catalytic subunit α and
loss-of-function mutations of PTEN.7,8 Buparlisib (BKM120) is a
novel, oral pan-PI3K inhibitor. Recently, buparlisib combined with
paclitaxel showed improved efficacy in the treatment of R/M
SCCHN patients over paclitaxel alone, suggesting the importance
of PI3K inhibition.9 We therefore conducted a Phase 2 study of
buparlisib in R/M SCCHN.
To overcome the limited predictive value of conventional
preclinical models, patient-derived tumour xenograft (PDX)
models are a promising advance in oncology.10–12 These models,
created by direct implantation of the patient’s tumour into
immunodeficient mice, preserve histologic and genetic
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characteristics of the original patient tumours. They have been
shown to be predictive of clinical outcomes and are being used for
translational research, preclinical drug screening and biomarker
identification/validation.13–15 The mouse–human co-clinical trial is
a new concept in which the treatment of interest is simultaneously
tested in patients and PDX models derived from tumours of the
patients enrolled in the clinical trial.15 This provides a platform to
develop new combination treatments, identify predictive biomar-
kers and provide insights into resistance mechanisms.
We conducted a co-clinical trial mirroring an ongoing clinical
study to identify predictive markers and optimal combinational
strategies. We established PDX models that faithfully replicated
the histologic, genomic and drug responses observed in the
corresponding patients. We tested the efficacy of a combination of
buparlisib and cetuximab on the PDX models. Based on the
results, we revised the clinical trial protocol to treat patients with a
combination of buparlisib and cetuximab, with promising results.
METHODS
Study design
This was a multicentre, Phase 2 study of buparlisib (100 mg/day)
monotherapy in patients with R/M SCCHN who had progressed on
platinum-based chemotherapy. The primary endpoint was disease
control rate (DCR). Secondary endpoints included RR, progression-
free survival rate (PFS), overall survival (OS) and safety.
Patients with histologically confirmed R/M SCCHN were
enrolled. Patients were at least 18 years old and had an Eastern
Cooperative Oncology Group performance status (ECOG-PS) of
0–2, at least one measurable disease and documented progressive
disease after platinum-based chemotherapy for R/M SCCHN.
Patients received continuous oral buparlisib (100mg/day) until
disease progression, death or unacceptable adverse events (AEs).
Treatment cycles were 28 days long. Drug doses were withheld
and/or reduced for intolerable grade 2 or grade 3/4 toxic effects. A
maximum of two dose-level reductions was permitted (80 mg,
then 60mg).
Response evaluations were defined according to RECIST 1.1
guidelines.16 Radiographic imaging was conducted at week 4,
then at every 8 weeks thereafter until disease progression or when
clinically indicated. Safety assessments included physical exam-
inations, documentation of AEs and laboratory measurements on
day 1 of each cycle. AEs were graded according to the Common
Terminology Criteria for Adverse Events version 4.0. This study was
conducted under approval by the institutional review boards of
Severance Hospital and all patients provided informed consent.
We revised the treatment protocol to the combination for
patients that progressed under buparlisib monotherapy. This
revised protocol was approved by the institutional review boards
of Severance Hospital. After protocol amendment, 11 patients
were treated with buparlisib/cetuximab.
PDX models
A total of seven tumour samples were obtained from four patients
(YHIM-01, -02, -06 and 07) with R/M SCCHN treated with buparlisib
in the Phase 2 trial and from three patients (YHIM-03, -04 and 05)
with SCCHN who had undergone surgery. Tumours and paired
peripheral blood samples were collected prior to initial buparlisib
treatment.
Six- to 8-week-old female severe combined immunodeficient
(NOG) and nude (nu/nu) mice (OrientBio, Seoul, Korea) were used
as recipients. After completion of experiments, we sacrificed mice
by inhalation of anaesthetics with CO2. All mice models were
maintained in the specific pathogen-free facility of the Avison
BioMedical Research Center (ABMRC) Animal Research Center at
Yonsei University College of Medicine. All methods were
performed in accordance with the guidelines of the Animal
Research Committee of Yonsei University College of Medicine and
were approved by the Association of Assessment and Accredita-
tion of Laboratory Animal Care. Patient tumour samples were cut
into ~3mm cubes and implanted subcutaneously into six or seven
mice for each patient. When tumours grew to 1.5 cm in diameter,
they were excised, dissected into ~3-mm cubes and implanted
into another set of mice by the same procedure. The passage
harbouring the patient-derived material was termed F0, with
subsequent generations numbered consecutively (F1, F2, etc.). The
rest of the carcinoma was cryopreserved and processed for
biological studies. Tumour cells from the third passage (F3) were
expanded for the in vivo drug efficacy test.
PDX-derived cell models
F3 tumours were excised and chopped and/or sliced. Spill-out cells
were also collected. Samples were incubated with collagenase/
dispase II for 1 h at 37 °C in phosphate-buffered saline (PBS) and
pelleted at 1500 r.p.m. for 10 min. The cell pellet was gently
resuspended in RPMI-1640 culture medium and cells were plated
onto collagen-coated culture surfaces. Cultures were kept in a
humidified 5% CO2 atmosphere at 37 °C. On the following day,
cultures were washed twice with PBS (37 °C) to remove cell debris
and nonadherent blood cells. Mouse Cell Depletion (MACS, 130-
104-694) and Cancer Isolation (MACS, 130-108-339) Kits were used
to enrich for human tumour cells. The EpCAM-positive cell
subpopulation in primary cultures was analysed using flow
cytometry. Successfully established models were free of stromal
cells and maintained a >95% EpCAM-positive cell subpopulation.
The medium was replenished with fresh medium every 3 days.
In vivo drug tests
When tumour volumes reached 200–250mm3, mice were
segregated into treatment groups based on tumour volume,
growth rate and mouse weight. Vehicle (5 mM citrate buffer) was
administered to the control group. Ten mice per group were
randomised and treated with vehicle or buparlisib (35 mg/kg, QD,
oral) alone or in combination with cetuximab (10 mg/kg, Q3D,
intraperitoneally).
Tumour dimensions were measured twice a week with a digital
calliper and tumour volume was calculated by the following
formula: tumour volume= [length × width2]/2. Percentage tumour
growth inhibition [%TGI= 1− (change of tumour volume in
treatment group/change of tumour volume in control group) ×
100] was used for the evaluation of anti-tumour efficacy.15
Cell viability assays
Cells were seeded at 3000/well in 96-well clear-bottom micro-
plates, incubated overnight and subsequently treated with drugs
for 3 days. Cell viability was analysed using CellTiter-Glo according
to the manufacturer’s protocol. IC50 values were calculated using
v5.0 GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA).
Drugs used were cetuximab (Selleckchem A2000) and BKM120
(Selleckchem S2247). Combination indices (CIs) were calculated
using the CacluSyn method.17 For colony formation assays, single
cells were seeded onto 6-well plates at a density of 3000/well.
After overnight attachment, cells were treated for 14 days.
Medium including drugs was replaced every 3 days. After
treatment, cells were washed with PBS, fixed in 4% paraformalde-
hyde in PBS for 10 min and stained with 0.5% crystal violet in 20%
methanol for 20 min. To evaluate clonogenicity, images were
captured using a flatbed scanner and cells were dissolved with
20% acetic acid in 20% methanol. The optical density of each well
was read at 570 nm using a SpectraMax 250 microplate reader
(Molecular Devices).18
Immunoblot analysis
Cell lysates containing equal amounts of protein were separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
transferred to a membrane, and then probed with primary and
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secondary antibodies. Signals were detected with SuperSignal™
West Pico Chemiluminescent Substrate (Thermo Fisher Scientific,
MA, USA). Primary antibodies were against cyclin B (Cell Signa-
ling Technology, cat. no. 122231), cyclin D (Cell Signaling
Technology, cat. no. 8396), cyclin E (Santa Cruz Biotechnology,
cat. no. 481), cleaved poly (ADP-ribose) polymerase (PARP) (Cell
Signaling Technology, cat. no. 5625), cleaved caspase-3 (Cell
Signaling Technology, cat. no. 9664), cleaved caspase-7 (Cell
Signaling Technology, cat. no. 8438), BCL-2 (Cell Signaling
Technology, cat. no. 2872), cleaved caspase-9 (Cell Signaling
Technology, cat. no. 7237) and Myc (Cell Signaling Technology,
cat. no. 9402). After washing, blots were probed with horseradish
peroxidase-conjugated rabbit secondary antibodies (Cell Signaling
Technology, Boston, MA, USA, cat. no. 7074). The membrane was
stripped and re-probed with an anti-β-actin (Sigma-Aldrich, cat.
no. A3854) antibody as an internal control.
Histology
Tissues from all PDX models were harvested and fixed in 10%
buffered formalin within 30 min of resection, and then processed
by routine procedures after 24 h fixation. Sections were stained
with haematoxylin and eosin (H&E) and reviewed by a pathologist
to confirm SCCHN.
Whole-exome sequencing (WES) and somatic variants
WES was used to identify somatic single-nucleotide variations or
substitutions (SNVs) and short insertions/deletions (indels) by
comparing the tumour genomes with matched normal genomes.
To minimise false positives from xenocontamination, sequencing
reads from host (mouse) genomes were filtered out from those
from tumour (human) genomes using the Xenome software.19
Matched normal genomes were prepared from patients’ periph-
eral blood. Exome-captured DNA by Agilent SureSelect Human All
Exome 50 Mb Kit (Agilent, USA) was used to prepare libraries and
100-bp paired-end sequencing was performed using an Illumina
HiSeq2000 platform (Illumina, USA). Alignment of sequencing
reads onto the human reference genome (hg19) was performed
using BWA-MEM (Burrows–Wheeler aligner-mem).20 Local realign-
ment and score recalibration of sequencing reads were performed
using Genome Analysis ToolKit (GATK).21 SNVs and indels (somatic
mutations, hereafter) were identified by MuTect and Indelocator,22
respectively, and collectively analysed as somatic mutations of
PDTX tumours. Somatic copy number alterations (SCNAs) were
identified by comparing the sequencing depth of tumour and
matched normal genomes using Excavator.23
Targeted deep-sequencing and germline variants
Genomic DNA from formalin-fixed paraffin-embedded (FFPE) or
fresh tissue, prepared using the QIAamp DNA FFPE Tissue Kit
(Qiagen) or DNeasy Blood and Tissue Kit (Qiagen), was screened for
244 cancer-related genes using a customised SureSelect Kit (Agilent
Technologies, Santa Clara, CA, USA) (Supplementary Table S1).
Targeted sequencing was performed using an Illumina HiSeq2000
with an average coverage depth of 500–1000×. The BWA20 with a
hybrid human (hg19) and mouse (mm10) genome was used to
separate 100-bp paired-end sequence reads at PDX-F2 into human
and mouse reads. Each read was aligned to both genomes and the
best-matched read of the human genome was established.24 After
pre-processing, the GATK21 was used for mark duplication, local
realignment and base quality-score recalibration of the reads. The
GATK Haplotype caller was run to identify germline mutations. Poor-
quality variants were filtered out using GATK VariantFiltration with
the following criteria: read depth < 20, quality by depth < 2.0, Fisher
strand > 60.0, root-mean-square mapping quality (MQ) < 20.0,
MQRankSum<−12.5, ReadPosRankSum<−8.0 and mutant allele
frequency (MAF) < 0.2. ANNOVAR25 was used for variant annotation,
and the CIVIC26 and DoCM27 databases were used to annotate
mutations that could be used for targeted therapy.
RNA-sequencing-based gene expression profiling
To identify changes in gene expression, we used RNA-sequencing.
A cDNA library was generated and 100 bp paired-end sequencing
was performed using Illumina HiSeq2000 (Illumina, USA). Splice-
aware alignment was conducted using the TopHat aligner.28
Gene-level summaries of expression levels into fragments per
kilobase million were performed using CuffLinks software.28
Visualisation
Oncoprint heatmaps were drawn for the patterns of overall
mutations using the ComplexHeatmap.29 Lollipop plots were
created for frequently mutated genes using MAFtools,30 which
offers a multitude of analysis and visualisation modules that are
commonly used in cancer genomic studies, to identify the
recurrence of genomic loci with variants.
Statistical analyses
A Simon’s two-stage design was used to test the null hypothesis
(P0) with a 10% significance level that the objective response rate
(ORR) is ≤30% vs. the alternative hypothesis (P1) that the ORR is
≥45%. The expected sample size is 48 patients to provide 80%
power to reject P0 when the true ORR is 45%. Twenty-three will be
accrued during stage I, and if six or fewer responses are observed
in the first stage, the trial is stopped early. Allowing for a follow-up
loss rate of 10%, the total sample size is 53 patients. Based on the
preclinical data, protocol amendment was in progress and at that
time 42 patients were enrolled. After protocol amendment,
additional 11 eligible patients were treated with buparlisib+
cetuximab after failure to buparlisib.
Results are presented as the mean ± standard deviation of at
least three experiments for each group. Statistical differences were
determined using analysis of variance and the Wilcoxon’s rank-
sum test for independent samples. Kaplan–Meier method was
used to depict survival distribution, and the log-rank test was used
for comparison. DCR was defined as the percentage of patients
showing complete response (CR), partial response (PR) and stable
disease (SD) to treatment based on RECIST 1.1. RR was defined as
the percentage of patients who had achieved CR and PR based on
RECIST 1.1. PFS was defined as the time from the initiation of
therapy until evidence of disease progression or death. OS was
defined as the time from the initiation of therapy until death from




A total of 53 patients were enrolled, of which 7 were excluded due
to rapid progression or withdrawal. Patient characteristics
included median age 55 years (range, 31–82); male (85%); ECOG
performance status 0/1/2 (11%/76%/13%); locoregional/meta-
static/both (30%/32%/38%); oral cavity/oropharynx/larynx primary
(36%/30%/13%); prior chemotherapy regimens 1/≥2 (38%/62%;
Table 1).
In the buparlisib monotherapy phase, 35 patients were
evaluated. DCR was 49% and RR was 3% (Fig. 1a). After protocol
revision, 11 patients who showed progression under buparlisib
monotherapy were treated with the combination of buparlisib and
cetuximab. In the combination phase, DCR was 91% and RR was
18% (Fig. 1b). Median PFS for buparlisib, followed by combination
therapy was significantly longer than that for buparlisib mono-
therapy (63 and 111 days, P= 0.039; Fig. 1c). Median OS for
buparlisib followed by combination therapy tended to be
prolonged compared to that for buparlisib monotherapy (148
and 205 days, P= 0.19; Fig. 1d).
Treatment-related AEs are summarised in Supplementary
Table S2. Grade 3–4 AEs were reported in 18 of 35 patients in
the buparlisib monotherapy group and 4 of 11 patients in the
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combination phase. The most common grade 3–4 AEs were
hyperglycaemia (10 in the buparlisib monotherapy vs. 3 in
combination phase). Treatment discontinuation for AEs occurred
in 19 patients in buparlisib and 3 in combination phase.
Treatment-related toxicities were not significantly increased by
the combination.
Genomic fidelity of PDX tumours in terms of somatic mutations
We performed targeted deep sequencing to detect somatic
mutations in seven original tumour (F0) and PDX-F2 tumour pairs
to determine whether F0 and F2 samples would exhibit identical
mutations. The coincidence of most germline mutations indicated
that F0 and F2 samples were nearly identical, with Jaccard
similarity index scores of >80% for most.30 Of the F0 germline
mutations identified in the F2 specimens, YHIM-02 and YHIM-01
received the highest scores of 94% and 92%, respectively
(Supplementary Fig. S1). The MAF values for F0-common and
F2-common mutations exhibited overall concordance (R= 0.89
and 0.95 for YHIM-01 and YHIM-02, respectively), suggesting that
most mutations in the F2 samples corresponded with those in the
F0 samples (Supplementary Fig. S1).
Faithful replication of clinical responses to buparlisib and
cetuximab in PDX models
We established YHIM-01, -02, -06 and -07 directly from advanced
R/M SCCHN patients who were treated in this Phase 2 trial. In
addition, YHIM-03, -04 and -05 were established from surgically
resected or biopsied SCCHN patients (Supplementary Table S3).
Tissue sections from these models were characterised using
H&E staining and p63 immunohistochemistry (IHC; Supplementary
Fig. S2). The histology of PDX tumours (F2) matched well with that
of primary tumours (F0) by both methods. Xenografts expressed
squamoid features, including keratinisation and intercellular
bridges, found in the original tumours. In seven established F3
generation PDXs, we tested buparlisib or cetuximab alone, or in
combination.
To evaluate whether preclinical responses in PDX models
mimicked the clinical response in patients, we treated YHIM-01,
-02, -06 and -07 with buparlisib, in parallel with the corresponding
R/M SCCHN patients from whom the PDX tumours were derived,
in a prospective trial. We observed that preclinical responses to
buparlisib in YHIM-01, -02, -06 and -07 precisely replicated the
clinical responses of their corresponding patients (Fig. 2a–c). All
seven established PDX models had a strong resistance to
buparlisib monotherapy, displaying rapid tumour progression
within a period of 30 days. Furthermore, marked tumour
regression was observed in buparlisib/cetuximab combination
therapy compared with buparlisib monotherapy in all PDX
models. Notably, YHIM-05, -06 and -07 demonstrated strong
resistance to each monotherapy, but treatment with buparlisib/
cetuximab showed more prominently and synergistically inhibited
the tumour growth than each buparlisib or cetuximab mono-
therapy [the average TGI (%) in YHIM-05, 114.92% of buparlisib/
cetuximab vs. 58.59% of buparlisib (P < 0.0001) and vs. 20.65% of
cetuximab (P < 0.0001); in YHIM-06, 98.01% of buparlisib/cetux-
imab vs. 42.37% of buparlisib (P < 0.001) and vs. 78.63% of
cetuximab (P < 0.001); in YHIM-07, 102.09% of buparlisib/cetux-
imab vs. 52.24% of buparlisib (P < 0.001) and vs. 76.72% of
cetuximab (P < 0.05)] (Fig. 2a and Supplementary Table S4). Data
from the PDX and clinical trials were comprehensively integrated
to identify predictive biomarkers of buparlisib.
Based on the strong synergy observed in the PDX models, we
revised the treatment protocol to the combination for cases that
progressed under buparlisib monotherapy. After protocol revision,
11 patients were treated with buparlisib/cetuximab. In the
combination phase, PR was observed in 18% and SD was 46%
in patients who had failed to respond to buparlisib (Fig. 1b).
Interestingly, the patient corresponding to YHIM-07 was
enrolled and treated with buparlisib/cetuximab after progression
under buparlisib monotherapy based on the revised protocol.
Indeed, the response of this patient was similar to that of YHIM-07
(Fig. 2d). After one cycle of buparlisib, the neck node showed
progression; however, after adding cetuximab, the neck node
improved, showing PR (Fig. 2d). Thus, this patient showed strong
synergistic inhibition with the combination, recapitulating the
responses observed in the corresponding PDX model. Taken
together, faithful replication of the clinical efficacy of buparlisib/
cetuximab in PDX highlights the potential of co-clinical trials to
inform and predict clinical outcomes.
Analysis of somatic mutation profiles in PDX tumours
Given the similarity of drug sensitivities between xenografts and
patients, we set out to identify predictive biomarkers of buparlisib
and cetuximab using the genetic and transcriptomic profiles of
PDX tumours. Somatic mutations in known cancer-related genes
based on the Cancer Gene Census29 are shown in Fig. 3a and
Supplementary Table S5. Recurrent non-silent mutations (≥2) in 10
genes (TP53, SETBP1, FAT1, BCL9, CDKN2A, MECOM, TGFBR2, ERBB2,
KAT6B and NOTCH1) are shown with mutation types (e.g. missense
and nonsense). The annotated amino-acid residue changes of
these mutations along with those of singletons are listed in
Supplementary Table S5. The most common mutations were TP53
mutations (YHIM-01, -02, -03, -06 and -07). Mutations in FAT1,
CDKN2A, NOTCH1 and TGFBR2 have been reported to be frequent
in SCCHN; all mutations of these loci in our cohort were found to
be truncating (either as nonsense or frameshift) and often
appeared as a double hit, suggestive of inactivation of both
alleles (i.e. YHIM-06 and -07 showed nonsense and frameshift
Table 1. Baseline patient characteristics.











Never smoker 16 37
Smoker 37 63
Time from initial diagnosis to study entry (month)
Median (range) 39 (5–159)
Primary site




Sinus (nasal, maxillary and ethmoid) 6 11




Number of prior chemotherapy regimens
1 20 38
≥2 33 62
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mutations for FAT1 and NOTCH1, respectively). However, no
PIK3CA mutations or recently reported novel SCCHN-related
mutations, such as AJUBA and NSD1, were found.
We also examined singleton mutations in cancer-related genes.
Of note, YHIM-05 harboured mutations in HRAS and CASP8, but
retained wild-type TP53, which is expected to have favourable
clinical outcomes, and a deficit of SCNAs7 was found as a synergy
group. For the recurrent cancer-related genes shown in
Supplementary Table S5, no mutations showed significant
enrichment toward cases with synergy; this was also true for the
remaining non-silent mutations in all the mutated genes. The
somatic mutations identified in seven cases are presented in
Supplementary Table 6.
The mutation rates (i.e. the number of exonic mutations per Mb)
for all seven PDX models are shown in Fig. 3a. Cases correspond-
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Fig. 1 Clinical response the patients enrolled in clinical trial. a, b Best tumour volume change from baseline in patients with at least one
post-baseline measurement a for buparlisib monotherapy, and b for the buparlisib/cetuximab combination phase. c Kaplan–Meier curves for
progression-free survival. (d) Kaplan–Meier curve for overall survival. (e) Duration of response.
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burdens (6.3–7.8 mutations/Mb) compared with the others (YHIM-
01, -02, -03 and -04) (1.7–6.7 mutations/Mb) (P= 0.075). The
relative proportions of missense mutations as well as mutation
signatures are illustrated in Fig. 3a. The nonsynonymous/synon-
ymous ratio was relatively low (<2.0) for four cases (YHIM-01, -03,
-05 and -06), suggesting that xenocontamination was still
substantial and may have produced elevated mutation rates for
those cases (asterisks in Fig. 3a). Mutation signature analysis
revealed age-related signatures (signatures 1A and 1B; annotated
as previously proposed)31 that were universally observed across
the genomes examined (17–46%). Previous signature analyses on
TCGA head and neck cancer genomes revealed that APOBEC,
smoking and ultraviolet radiation-related signatures (signature 2/
13, 4 and 7, respectively) comprise the major mutation signatures
of SCCHN.7 In this study, these signatures were observed in 4, 2
and 1 case(s), respectively.
We also investigated somatic mutations in 31 patients from
whom tumour tissue was available. Significant genetic alterations
related to drug response were not observed (Supplementary
Fig. S3). Because there were no matched normal samples for these
31 patients, we investigated all the mutations of these samples
using HaplotypeCaller. Thereafter, to assess the cancer-specific
mutations, we employed CIVic26 and DoCM,27 which are
specialised databases for interpretation of cancer mutations.
Consequently, there were no targetable mutations, such as PIK3CA
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Erbitux 10 mg/kg vs. BKM120 35 mg/kg + erbitux 10 mg/kg 
BKM120 35 mg/kg vs. BKM120 35 mg/kg + erbitux 10 mg/kg  






Fig. 2 Drug responses of PDX models and corresponding patients. a Buparlisib, cetuximab and buparlisib/cetuximab tested in PDX models.
b Correlation between patient YHIM-01 and PDX treated with buparlisib. c Rapid progression of patient YHIM-02 and PDX under buparlisib
monotherapy. d Response of patient YHIM-07 to buparlisib/cetuximab therapy after progression under buparlisib monotherapy. After one
cycle of buparlisib, the neck node progressed; however, it improved after the addition of cetuximab. Pink arrowhead indicates the measurable
target tumour lesions.
Mouse–human co-clinical trials demonstrate superior anti-tumour. . .


























Fig. 3 Genetic alteration profile in patient-derived xenograft models. a Somatic mutations in known cancer-related genes based on the
Cancer Gene Census for all seven PDX models (first panel); mutation rates for all seven PDX models (second panel); relative proportions of
functional consequences (third panel); and signatures (fourth panel). b Genome-wide somatic copy number alteration profiles of seven PDX
models using whole-exome sequencing data. Asterisks indicate the cases with NS/S (nonsynonymous/synonymous) ratios less than 2.0.
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Fig. 4 In vitro experiments for cell proliferation in the PDX models showing synergy of buparlisib/cetuximab. a Comparison of gene
expression profiles between buparlisib, cetuximab, buparlisib/cetuximab and control in PDX models YHIM-05, -06 and -07, showing that genes
associated with apoptosis and cell-cycle arrest were significantly upregulated by combination therapy. b Cell viability as a function of drug
treatment of cell lines from PDX models YUX-06 and -07). c Expression of genes related to cell-cycle progression (cyclins B, D and E) and
apoptosis (cleaved PARP, cleaved caspase-3 and cleaved-7) in YUX-06 and -07. d IHC showing proliferative (Ki67) and apoptotic (TUNEL)
markers in YHIM-06 and -07. e Flow cytometry showing apoptosis in YUX-06 and -07.
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mutations. Supplementary Figure S3A was drawn to confirm the
pattern of the cancer-specific mutations. TP53 (1 for L72Q, 1 for
Y166C, 1 for Y181C, 1 for R209W, 2 for R234H), MLH1 (3 for V384D),
CDKN2A (1 for R80X, 1 for W110X), STK11 (1 for P281L) and MAPK1
(1 for E332K) mutations were included in the CIVic and DoCM
databases. Supplementary Figure S3B is a needle plot showing the
hotspot mutations of TP53.
Copy number alteration profiles in PDX tumours
SCNAs were evaluated using WES data. Genome-wide SCNA
profiles of seven cases examined are illustrated in Fig. 3b.
Recurrent losses were observed in 3p and 10p, along with
recurrent gains in 3q, 5p, 8q, 9p/q, 12q and 20p/q, consistent with
the previously reported frequencies of SCNA in SCCHN genomes.7
We also examined focal, gene-level amplifications or deletions of
genes previously reported to be related to SCCHN,7 including the
locus chr9:1–17Mb (Fig. 3b). Of note, the amplification of PIK3CA
and JAK2 was relatively frequent for YHIM-05, -06 and -07, and
EGFR amplification was observed in YHIM-06 and -07 (Fig. 3b).
Combination treatment upregulated genes associated with
apoptotic and cell-cycle arrest
To elucidate the mechanism underlying the synergistic effect of
buparlisib and cetuximab, we performed a comparative analysis of
gene expression in YHIM-05, -06 and -07 at baseline, after
buparlisib or cetuximab alone and after combination therapy.
Genes associated with apoptotic and cell-cycle arrest were
significantly upregulated with combination therapy compared
with that after each buparlisib or cetuximab monotherapy. In
contrast, the expression of genes related to anti-apoptotic and
cell-cycle progression was downregulated (Fig. 4a).
To explore the mechanism of combination therapy, we
performed cell viability assays and immunoblots using PDX-
derived tumour cell lines from YUX-06 and -07 (YHIM-06 and -07).
The combination of buparlisib with cetuximab induced a
synergistic anti-tumour effect, as evidenced by CI < 1 (CI value,
0.628 (YUX-06); 0.756 (YUX-07)) and induced apoptosis (Fig. 4b).
Dual inhibition of the EGFR and PI3K pathways induced the
downregulation of molecules related to cell-cycle progression
(cyclin B, cyclin D and cyclin E) and upregulation of molecules
related to apoptosis (cleaved PARP, cleaved caspase-3 and
caspase-7) to greater extents than single inhibition (Fig. 4c). The
combination treatment significantly increased apoptosis and
decreased proliferation in YHIM-06 and -07 based on IHC (P <
0.001; Fig. 4d). Moreover, apoptosis was dramatically increased in
YUX-06 and -07 by flow cytometry (P < 0.001; Fig. 4e). In YUX-01
and -02, the levels of Bcl-2, cleaved caspase-9 and Myc were not
changed by buparlisib monotherapy; however, increased cleaved
caspase-9 and decreased Bcl-2 and Myc were observed after
cetuximab as well as after buparlisib/cetuximab combination
therapy (Supplementary Figure S4).
DISCUSSION
This study showed that the pan-PI3K inhibitor buparlisib was
insufficient for the treatment of patients with R/M SCCHN, even
though PI3K pathway alterations are frequently caused by
mutations associated with SCCHN.7,8 We conducted a
mouse–human co-clinical trial, with PDX models derived from
biopsied tumour samples of the patients enrolled in this Phase 2
clinical trial. This co-clinical trial indicated that all PDX models
were resistant to buparlisib monotherapy, while some PDX models
showed remarkable sensitivity to the combination of buparlisib/
cetuximab. Based on these results, we revised the clinical trial
protocol and switched patients who failed to respond to
buparlisib monotherapy to the combination of buparlisib/cetux-
imab. The combination improved treatment outcomes without
any significant increase in treatment-related toxicities.
Transcriptomic analyses indicated that genes related to apoptosis
and cell-cycle arrest were significantly upregulated upon combi-
nation treatment compared with treatment with buparlisib or
cetuximab alone.
We successfully established PDX models from R/M SCCHN patients
and conducted a co-clinical trial in parallel with a Phase 2 clinical trial.
We demonstrated that histologic and genetic characteristics were
highly preserved between patient tumours and corresponding PDX
tumours. Although the PI3K–AKT–mTOR pathway is frequently
activated in SCCHN,7,8 the efficacy data from the clinical trial as well
as from PDX models showed the tumour to be highly resistant to
buparlisib monotherapy. Our findings indicated that the combination
treatment induced a synergistic anti-tumour effect as evidenced by
CI < 1, and induced apoptosis and cell-cycle arrest. To exclude exactly
that combination regimen is not the effect of cetuximab mono-
therapy, the clinical study design comparing combination (buparli-
sib/cetuximab), buparlisib monotherapy and cetuximab
monotherapy is necessary. There were lots of clinical trials with
cetuximab monotherapy in head and neck cancer patients. In
general, the RR of cetuximab monotherapy has been known as
10–20%,32 even though the RR was different depending on the trials.
To identify predictive genomic alterations in response to
combination therapy, we conducted comprehensive genomic
and transcriptomic analyses of the baseline and on-treatment
tumour samples. Unexpectedly, predictive genomic alterations
upon combination therapy were not observed in either PDX or
patient samples, which would be limited by a small sample size.
Expression of genes associated with apoptosis and cell-cycle arrest
was significantly upregulated by combination treatment. These
preclinical data strongly suggest that combination therapies with
buparlisib and cetuximab exert their effects by facilitating
apoptosis and cell-cycle arrest. Thus, the therapeutic strategy of
PI3K inhibitor plus EGFR monoclonal antibody could improve
treatment outcomes in R/M SCCHN patients.
Treatment-related toxicities must be considered when devel-
oping combination therapies for cancer patients. Known AEs
associated with buparlisib, including hyperglycaemia and gastro-
intestinal AEs (e.g. stomatitis, diarrhoea, nausea and vomiting),
could be managed with the established strategies of dose
reduction and treatment of symptoms with appropriate con-
comitant medication. Moreover, the occurrence of AEs related to
cetuximab, including skin rash, mucositis or diarrhoea,3 was not
increased in patients by the combination therapy. However, in the
combination phase of this study, patients are congruent with the
AE of these combined agents and high discontinuation rate. This
study has a limitation that only 11 patients were treated with
buparlisib/cetuximab after revising the protocol, which is a small
number. Thus, cautious interpretation and additional clinical trials
are needed to confirm our results.
To our knowledge, this is the first study demonstrating the
additive or synergistic effects of buparlisib and cetuximab in a
clinical trial based on preclinical PDX data, which can significantly
contribute to the clinical development of PI3K inhibitors in R/M
SCCHN patients. A combination of buparlisib/cetuximab may
overcome resistance to buparlisib and represent a more effective
option for treating patients with R/M SCCHN.
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